Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bioventus Inc. - Class A Common Stock (NQ:BVS)

14.51 +0.09 (+0.62%)
Delayed Quote Updated: 3:13 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bioventus Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Bioventus Reports Second Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Examining the Future: Bioventus's Earnings Outlook ↗
 
Via Benzinga
News headline image
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus Reports First Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
From Bioventus, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gapping stocks in Tuesday's session ↗
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million ↗
Bioventus posted strong Q4 results, with EPS and revenue surpassing estimates. The company projects 2025 sales of $560M–$570M and adjusted EPS of $0.64–$0.68. 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 11, 2025 ↗
 
Via Benzinga
News headline image
Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
S&P 500 Gains 1%; Vimeo Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September ↗
 
Via Benzinga
News headline image
Bioventus Reports Third Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Solventum Stock Earns 81 RS Rating ↗
Solventum stock saw a positive improvement to its Relative Strength Rating on Tuesday, with an upgrade from 78 to 81. 
Via Investor's Business Daily
News headline image
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Executives Buying W. P. Carey And 2 Other Stocks ↗
 
Via Benzinga
News headline image
Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
From Bioventus, Inc.
Via GlobeNewswire
News headline image
BVS Stock Earnings: Bioventus Beats EPS, Beats Revenue for Q2 2024 ↗
BVS stock results show that Bioventus beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.